Class I Recall of SpF PLUS-Mini and SpF XL IIB Implantable Spinal Fusion Stimulators by Zimmer Biomet

PUBLISHED: May 30, 2017
Source: Food and Drug Administration
Relevant to: Hospital

Zimmer Biomet is recalling the SpF PLUS-Mini and SpF XL IIb Implantable Spinal Fusion Stimulators due to higher than allowed levels of potential harmful chemicals, which may be toxic to tissues and organs (cytotoxicity) and that were found during the company's routine monitoring procedure. A cytotoxicity test is a part of the biological evaluation of medical devices to ensure compatibility with the device and the human body. A positive cytotoxicity test (failed result) can indicate that a device contains potential harmful chemicals at amounts or levels that could be dangerous to the patient.

The use of affected product may cause serious adverse health consequences, including but not limited to chronic infections, long-term hospitalization due to additional surgical procedures, paralysis, and death.

See the Recall Notice for a list of affected serial numbers.

Distribution Dates: March 28, 2017 to April 6, 2017

Manufacturing Dates: October 11, 2016 to January 18, 2017

The Zimmer Biomet SpF PLUS-Mini and SpF XL IIb Implantable Spinal Fusion Stimulators are used during spinal fusion surgery to increase the possibility of permanently connecting two or more bones of the spine (backbone) together. The device is implanted into the patient's back and provides constant electrical stimulation to the surgical site.

On April 20, 2017 Zimmer Biomet sent an Urgent Medical Device Removal notification to all affected customers. The notice instructed customers to:

  • Review notification and distribute the information to all appropriate personnel.
  • Quarantine all affected products.

The Zimmer Biomet sales representative will remove the affected product from the facility.

If the product was purchased directly from the company, follow the instructions on the Certificate of Acknowledgment form provided by Zimmer Biomet to complete the return.

Surgeons are reminded that normal clinical monitoring is recommended for 3-6 months post operatively for any patient with the affected devices implanted.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.

Read the MedWatch Safety Alert, including a link to the FDA Recall Notice, at the link below.

Want to read the full alert and receive alert emails?

Browse Additional Alerts